Environmental genome project: focusing on differences to understand the whole. by Wakefield, Julie
Spheres of InfluenceA
s the Environmental Genome Project (EGP) marks its fifth
anniversary in 2003, there is some cause for celebration.
Although it is premature to expect the project to have any impact
on public health and policy yet, the EGP’s science and technology
are advancing in step with its original goals of understanding the
complex interrelationship between environmental exposure,
genetic susceptibility, and human disease. 
The NIEHS began the EGP in late 1997. The EGP is a multi-
component project comprising extramural and intramural research
in several key areas. In addition to enhancing understanding of
human genetic susceptibility to environmental exposure—how
individuals differ in susceptibility to environmental agents, and
how such susceptibilities change over time—other topics of interest
are dose response, identification of sensitive subpopulations, and
selection of appropriate test systems for human responses. EGP
research is also looking at selected genes in different individuals to
learn the extent and location of variations in a single DNA pair,
also called single nucleotide polymorphisms, or SNPs. SNP varia-
tions are thought to be central to why people respond differently to
various drugs or environmental toxicants.
The project’s findings have the potential to revolutionize
everything from assessing a chemical’s safety, to predicting a sub-
population’s adverse reactions to a new drug, to identifying earli-
er warning signs of much subtler effects. “The EGP will open up
a whole new vista of both public health and design of medicine—
molecular-designed medicines that specifically target genes that
have been modified because of SNPs,” says James Selkirk, deputy
director of the National Center for Toxicogenomics. The center is
a coordinated, multidisciplinary research program of the NIEHS
that has conducted the intramural research phase of the EGP.
Since its inception, the EGP has been closely tied conceptually
and through the collection of sequencing data to the Human
Genome Project, which was initiated in October 1990. The EGP
heavily relies on sequencing data produced from the Human
Genome Project and other related sequencing projects. “[Genome
mapping projects] that are going on right now are very important
tools for us in environmental health,” says William Farland, acting
deputy assistant administrator for science in the Office of Research
and Development at the U.S. Environmental Protection Agency
(EPA). “The kinds of data that we are getting out of these studies
will allow us to begin to identify working genes and gene products
that might be at the heart of understanding public health impacts,
interindividual variability, or susceptibility within populations.”
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The EGP has generated a working list of more
than 550 environmentally responsive genes
related to important cellular pathways such as
metabolism, DNA repair, and cell cycle con-
trol that are potential targets for resequencing
to identify each gene’s SNPs. So far the EGP
has experimentally identified 9,095 SNPs
from the 123 environmentally responsive
genes that have been resequenced to date, says
Joan Packenham, director of the EGP’s
Comparative Mouse Genome Consortium.
Work is under way to sequence another 200
of these genes.
The resequencing is taking place at the
University of Washington, and the findings
are being compiled into a central database of
gene SNPs at the University of Utah Genome
Center in Salt Lake City. Once researchers
understand the prevalence and distribution of
SNPs in those key genes, the next step is to
search specific genetically susceptible subpop-
ulations of individuals with given diseases,
such as heart disease, diabetes, and genetic
diseases. This could provide clues as to
whether SNPs in those specific genes are
related to disease formation.
Understanding what the genes actually do
is key. “Once we can identify and say ‘here it
is, here’s its variability’—that’s the easy ques-
tion,” says George Lucier, retired associate
director of the National Toxicology Program,
now an NIEHS consultant and an adjunct
senior toxicologist for Environmental
Defense. “We’re going to have to learn what a
lot of these genes do and how they are related
to toxic responses before we can use that
information in a widespread way in risk
assessment,” he says. Lucier encourages more
hypothesis-driven research using automated
DNA sequencing. Such research would probe
specific lines of queries rather than, for exam-
ple, just broadly collecting resequencing data. 
One EGP accomplishment of note is the
creation of the Comparative Mouse Genome
Consortium, which is working to develop
transgenic and knockout mouse models based
on variants among the environmental response
genes. This consortium of academic research
centers will use the mouse models to determine
the functional significance of human DNA
polymorphisms and analyze the function of
these polymorphic variants. The consortium’s
research portfolio includes extramural and
intramural studies to identify human DNA
polymorphisms in the population and epi-
demiological studies to track their prevalence. 
Development of technology to support
such research is sorely needed, according to
Daniel W. Nebert, an environmental health
and genetics researcher at the University of
Cincinnati. The kinks are still being worked
out with new tools. For example, the advent
of microarray technology means researchers
can look at the expression of a variety of
genes simultaneously. “This creates some
advantages—you can get information more
quickly—but you have to process it and sort
out what’s important and what’s just noise,”
Lucier says.
“We see that polymorphism or genome
technology will eventually probably merge
with microarray technology to help us search
for the actual phenotypes associated with sus-
ceptibility,” says Raymond Tennant, director
of the National Center for Toxicogenomics.
“But for now, we’re still searching to catalog
the various variants. That’s still a very formi-
dable task.”
Risk Assessment
To date, information from the EGP has been
slow to trickle into the policy-making arena.
“At this point the EGP has had very little
influence on any risk assessment that was
made. That doesn’t mean it doesn’t have
promise. But there’s really fear among all the
major players about how to use this sort of
information,” Lucier says.
Industry leaders fear this technology could
be used to call a chemical hazardous.
Conversely, environmental advocates fear that
industries could use this information to
misidentify their chemicals as safe. Regulatory
agencies, mindful of these fears, could be more
hesitant in applying the technology to their
own risk assessments, because they fear it lacks
credibility. “That doesn’t mean that it won’t
happen sometime in the future,” Lucier says. 
“[The EGP] will transform risk assessment,
but we’re approaching that very incremental-
ly,” Tennant agrees. Meanwhile, the volume of
data is still too small to draw any conclusions,
says Selkirk. First, the information needs to
mature, the assays need to be validated, and
researchers need to obtain a better understand-
ing of the relevance of particular changes in
gene expression and toxicity—for example,
what they mean in terms of dose response and
identification of sensitive subpopulations.
The genome data will help understand
responses to environmental toxicants and
allow for more accurate extrapolation of
experimental animal responses to human
populations, Farland says. Scientists will be
better able to predict how a chemical will
affect a certain mechanism once there is infor-
mation on how the chemical acts and what
pathways it disrupts.
Besides improving cross-species extrapola-
tion, the EGP will enable “the design of epi-
demiological approaches that allow us to
identify more subtle effects and therefore
identify either susceptibilities or adverse
impacts much earlier and much more quickly
than we might have,” Farland says. By testing
individuals for various SNPs, researchers and
clinicians ultimately will be able to predict
whether those individuals will be vulnerable
to a given chemical or whether a new drug
might be harmful to them. 
To expedite the process of identifying
both susceptible subpopulations and the
potential for adverse effects, researchers and
policy makers are starting to look to hypothe-
sis-driven research projects that will address
specific questions in toxicology, particularly as
it relates to structure–activity relationships
and identifying key gene expression events
and toxic responses. “As we then start enlarg-
ing that overall database, it will get easier and
easier to ask those questions, because we’ll
have a better framework in which to ask
them,” Lucier says. “If you understand why a
chemical is toxic, you can start predicting
what other chemicals might be toxic, better
understand dose–response relationships, bet-
ter identify a sensitive subpopulation. You
can use that information in risk assessment as
well as other public health policy activities.”
Experts believe the first applications
should be chosen from classes of chemicals for
which there is already sufficient background
information to know what the responses
mean, such as endocrine disruptors. Scientists
already know many of the genes that change
upon exposure to estrogens, for example. So
applying chemicals with unknown estrogenic
activity to that framework could show
whether they act like estrogens. The technolo-
gy may also be readily applied to dioxins and
some metals, says Lucier.
As the fruits of the EGP’s labors start
appearing in the scientific literature, the EPA
is beginning to bring the new data into risk
assessment. Farland says current risk assess-
ments for trichloroethylene, for instance,
which are under review, actually consider
these genetic factors and give some examples
where either lifestyles or existing conditions
or genetic factors could have an impact on
the degree of hazard and risk. 
“These are complex data sets, and in a
lot of cases we have to filter out the impor-
tant pieces of information from all of the
data that are there to try to understand the
implications for risk assessment,” he says.
“Until then, we’re going to take it on a case-
by-case basis. And we’re going to use the
process of peer involvement and peer review
to make sure the scientific community is
very much involved in the way that we use
some of this cutting-edge type information
in our work.” He adds that, in the future,
more cases will focus specifically on gene
changes and the range of genetic variation in
human populations.
Drug Development
Environmental genome data are also
wending their way into the drug develop-
ment and safety evaluation processes in
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mic and federal research centers. “The
Holy Grail is to discover gene changes
that are predictive of a toxic insult and
that can be used in early screening of drug
candidates,” says I. Y. Rosenblum, group
director of drug safety at the Schering
Plough Research Institute. In this way,
potential toxicities can be identi-
fied much earlier in the process,
saving millions of dollars in
development costs. 
“As we understand the reasons
why [some] people have adverse side
effects whereas most people don’t,
we can determine why a drug might
not be appropriate for
an individual who
expresses genes at a
higher level or lower
level than someone
else,” Lucier says. “No
one wins when a drug
that’s good for ninety-
eight percent of the
population has a bad
effect on two percent.
If we could identify the
two percent ahead of time, then [the
drug] would be used with a great
deal more confidence, especially
with a good efficacious drug for the
treatment of a particular disease.” 
Findings from the EGP and
the field of toxicogenomics may
also provide new drug discovery
targets by using genomics method-
ologies to help guide selection of
new candidate drugs to be put into
drug development, Rosenblum
says. “Many companies are aggres-
sively building up toxicogenomic
databases,” he says. “There are consortiums
trying to do this. The Food and Drug
Administration [FDA] is involved in some of
these efforts. Every major pharmaceutical
company I can think of, including smaller
biotech companies, are all engaged in some
aspect of doing this.” 
Rosenblum adds that the EGP may also
help better explain mechanisms of toxicity,
so candidate drugs might be modified to
eliminate certain toxicities. Without such
knowledge, “you may be throwing the baby
out with the bathwater,” he says.
The FDA is starting to look into whether
there are better ways to not only understand
susceptible members in the population but
also design better therapies. Environmental
genome data are already being incorporated
into evaluations in safety pharmacology, a
branch of safety evaluation that integrates the
best practices of pharmacology, physiology,
and toxicology. For example, people with a
certain type of metabolism—such as so-called
slow acetylators—may be more vulnerable to a
given carcinogen. Others may be protected
against certain classes of chemicals, because
they carry a genetic polymorphism for a
detoxifying metabolic process.
The pace of progress at the level of clinical
applications is also accelerating. Researchers
are attempting to define subpopulations who
will or will not respond positively to a thera-
peutic agent and those individuals that will
more likely to suffer a toxic response.
Environmental genome data have proven
helpful in several cases. In one, EGP
researchers at the University of Cincinnati
have identified gene variants that affect the
way individual asthma sufferers respond to
albuterol, a drug commonly used to control
acute attacks. They found a variant that can
produce 8,192 combinations, 12 of which
directly impact response to the medication.
Researchers may now be able to identify asth-
ma patients who will respond either well or
poorly to albuterol. 
Future Directions
Many challenges lay ahead for the EGP. “One
leading challenge is to have the bioinformatics
keep up with the data that are generated,”
Farland says. Statistical and computer models
for analyzing gene–environment interactions
are just a start. Methods to analyze macro-
molecular cellular components are also key.
Another leading challenge is narrowing the
field to identify the genes and pathways most
relevant to environmental health. 
As more information emerges from the
EGP, the complex ethical, legal, and social
issues entailed in delving so deeply
into an individual’s DNA are sure to
become more prominent. “In terms
of the policy issues, this is going to
get into some discussion of ethics
and the question of personal infor-
mation and how much one wants to
know about their genome and their
susceptibility to chemicals, and who
needs to know and things like that,”
Farland says. “These are the kinds of
things ethicists are now starting to
deal with, and at some point they’re
going to be entering into the debate
in a large way.”
Farland says agencies would like
to see this kind of information
extended into the understanding of
ecologic impacts as well. “There is a
fair amount of work going on that
will be looking at the use of these
types of data for assessing impacts on
fish and invertebrates as well,” he
says. “So even beyond the human
EGP, there will be some important
data coming through on some of
these other ecological species as
well.” Finally, says Farland, this
information may be called into ser-
vice as agencies get better at commu-
nicating with the public about their
risks from exposure to environmen-
tal chemicals.
In the future, Packenham would
like to see a large resequencing effort to
include other categories of environmentally
responsive genes such as those involved in sig-
nal transduction, apoptosis, oxidative stress,
and drug metabolizing enzymes. To improve
risk assessment, Packenham also advocates for
EGP data being used to support population-
based studies for the prevalence of high-risk
alleles for environmentally related disease.
Much has been learned about why indi-
viduals react differently to the same environ-
mental exposures, but with new findings
come new questions about the complex inter-
play between environmental exposure, genet-
ic susceptibility, and human disease—as well
as how to use the information. Despite the
unknowns, the EGP, with its potential for
revolution, is a powerful force, and the years
ahead should bring new insights into our
individual differences.
Julie Wakefield
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